304 related articles for article (PubMed ID: 17692541)
21. A hematopoietic-specific transmembrane protein, Art-1, is possibly regulated by AML1.
Harada Y; Harada H; Downing JR; Kimura A
Biochem Biophys Res Commun; 2001 Jun; 284(3):714-22. PubMed ID: 11396961
[TBL] [Abstract][Full Text] [Related]
22. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors.
Okuda T; Cai Z; Yang S; Lenny N; Lyu CJ; van Deursen JM; Harada H; Downing JR
Blood; 1998 May; 91(9):3134-43. PubMed ID: 9558367
[TBL] [Abstract][Full Text] [Related]
23. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis.
Ichikawa M; Asai T; Saito T; Seo S; Yamazaki I; Yamagata T; Mitani K; Chiba S; Ogawa S; Kurokawa M; Hirai H
Nat Med; 2004 Mar; 10(3):299-304. PubMed ID: 14966519
[TBL] [Abstract][Full Text] [Related]
24. Molecular mechanisms of leukemogenesis by AML1/EVI-1.
Mitani K
Oncogene; 2004 May; 23(24):4263-9. PubMed ID: 15156182
[TBL] [Abstract][Full Text] [Related]
25. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells.
Nimer SD; Moore MA
Oncogene; 2004 May; 23(24):4249-54. PubMed ID: 15156180
[TBL] [Abstract][Full Text] [Related]
26. AML1-ETO interacts with Sp1 and antagonizes Sp1 transactivity through RUNT domain.
Wei H; Liu X; Xiong X; Wang Y; Rao Q; Wang M; Wang J
FEBS Lett; 2008 Jun; 582(15):2167-72. PubMed ID: 18519037
[TBL] [Abstract][Full Text] [Related]
27. AML1 and AML1 fusion protein AML1-ETO in myeloid gene regulation and leukemogenesis.
Zhang DE; Burel S; Zhou L; Hetherington CJ; Yuan Y
Blood Cells Mol Dis; 2001; 27(2):368-76. PubMed ID: 11259158
[No Abstract] [Full Text] [Related]
28. Transformation properties of the ETO gene, fusion partner in t(8:21) leukemias.
Wang J; Wang M; Liu JM
Cancer Res; 1997 Jul; 57(14):2951-5. PubMed ID: 9230207
[TBL] [Abstract][Full Text] [Related]
29. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
[TBL] [Abstract][Full Text] [Related]
30. PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).
Zhang Y; Emmanuel N; Kamboj G; Chen J; Shurafa M; Van Dyke DL; Wiktor A; Rowley JD
Genes Chromosomes Cancer; 2004 Aug; 40(4):365-70. PubMed ID: 15188461
[TBL] [Abstract][Full Text] [Related]
31. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins.
Lou J; Cao W; Bernardin F; Ayyanathan K; RauscherIII FJ; Friedman AD
Oncogene; 2000 May; 19(22):2695-703. PubMed ID: 10851069
[TBL] [Abstract][Full Text] [Related]
32. The 8;21 translocation in leukemogenesis.
Peterson LF; Zhang DE
Oncogene; 2004 May; 23(24):4255-62. PubMed ID: 15156181
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein.
Fazi F; Racanicchi S; Zardo G; Starnes LM; Mancini M; Travaglini L; Diverio D; Ammatuna E; Cimino G; Lo-Coco F; Grignani F; Nervi C
Cancer Cell; 2007 Nov; 12(5):457-66. PubMed ID: 17996649
[TBL] [Abstract][Full Text] [Related]
34. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
Wang J; Saunthararajah Y; Redner RL; Liu JM
Cancer Res; 1999 Jun; 59(12):2766-9. PubMed ID: 10383127
[TBL] [Abstract][Full Text] [Related]
35. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
[TBL] [Abstract][Full Text] [Related]
36. Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation.
Aikawa Y; Nguyen LA; Isono K; Takakura N; Tagata Y; Schmitz ML; Koseki H; Kitabayashi I
EMBO J; 2006 Sep; 25(17):3955-65. PubMed ID: 16917507
[TBL] [Abstract][Full Text] [Related]
37. Establishment of a pluripotent preleukaemic stem cell line by expression of the AML1-ETO fusion protein in Notch1-immortalized HSCN1cl10 cells.
Delaney C; Bernstein ID
Br J Haematol; 2004 May; 125(3):353-7. PubMed ID: 15086416
[TBL] [Abstract][Full Text] [Related]
38. Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1.
Li X; Vradii D; Gutierrez S; Lian JB; van Wijnen AJ; Stein JL; Stein GS; Javed A
J Cell Biochem; 2005 Nov; 96(4):795-809. PubMed ID: 16149049
[TBL] [Abstract][Full Text] [Related]
39. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice.
Tsuzuki S; Seto M; Greaves M; Enver T
Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8443-8. PubMed ID: 15155899
[TBL] [Abstract][Full Text] [Related]
40. Discrimination of target by siRNA: designing of AML1-MTG8 fusion mRNA-specific siRNA sequences.
Kasashima K; Sakota E; Kozu T
Biochimie; 2004; 86(9-10):713-21. PubMed ID: 15556282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
